Short interest for OpGen gives investors a sense of the degree to which investors are betting on the decline of OpGen's stock. Short interest data is updated every two weeks.

OpGen Stock (NASDAQ:OPGN), Short Interest Report

OpGen

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

APCX

CDLX

MESO

OPGN

STOK

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday.

The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&amp;P 500 also rose, gaining, 0.17% to 5,227.03.

Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates

Movers

AKBA

BCAN

CEIX

CHEK

CISS

DADA

DERM

DNUT

EGOX

ETAO

GLUE

GOEV

GWAV

IPDN

IVVD

MRNO

NBSE

NGVC

NOVA

NUVB

PRAX

QRTEB

RDDT

SXTP

TIVC

TSLA

VKTX

WPRT

Shares of  Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss.

Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday.

The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&amp;P 500 also rose, gaining, 0.27% to 5,232.36.

Dow Gains 100 Points; McCormick Posts Upbeat Results

OpGen Inc

Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $92.767 million which missed the analyst consensus estimate of $94.995 million by 2.35 percent. This is a 68.99 percent increase over sales of $54.895 million the same period last year.

Earnings Beats

Earnings Misses

RKLB

Rocket Lab USA Q1 2024 GAAP EPS $(0.09) Beats $(0.10) Estimate, Sales $92.767M Miss $94.995M Estimate

Guidance

Symbotic Sees Q3 Revenue $450M-$450M vs $447.58M Est.

ASRT

Assertio Reiterates Guidance For 2024, Calling For Net Product Sales Of $110M-$125M (Est $117.35M) And Adjusted EBITDA Of $20M-$30M

&nbsp;GreenPower Motor Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/GPV#TSXV">GPV</a>) ("GreenPower" or the "Company"), a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announced it has commenced an underwritten public offering in the United States (the "Offering").
&nbsp;
The Offering consists of common shares and warrants to purchase common shares and is subject to market conditions. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size, pricing or other terms of the Offering. In addition, the Company intends to grant the underwriter a 45-day option to purchase up to an additional 5 percent of the number of common shares and/or warrants offered in the Offering. &nbsp;
Maxim Group LLC is acting as sole book-running manager for the Offering.

Offerings

TSXV:GPV

GreenPower Announces Proposed Public Offering Of Common Shares & Warrants; No Size Or Amount Disclosed

Cabot Sees FY24 Adj. EPS $6.65-$6.85 Vs $7.59 Estimate

Mueller Water Products Sees FY24 Consolidated Net Sales Flat To Down 2%, Increases Adj. EBITDA Expectations To Increase 23-27%

DZSI

DZS To Acquire NetComm; DZS To Pay $7M At Closing; Purchase Price Includes Additional Earn-Out Of Up To $3M If 2024 Revenue Of $87.5M Is Achieved With Such Earn-Out Structure Beginning At $72.5M Of 2024 Net Revenue

Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.77) by 1.3 percent. This is a 16.42 percent decrease over losses of $(0.67) per share from the same period last year.

PLRX

Pliant Therapeutics Q1 EPS $(0.78) Misses $(0.77) Estimate

Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. The company reported quarterly sales of $1.386 billion which beat the analyst consensus estimate of $1.371 billion by 1.08 percent. This is a 7.49 percent increase over sales of $1.289 billion the same period last year.

COTY

Coty Q3 2024 Adj EPS $0.05 Misses $0.06 Estimate, Sales $1.386B Beat $1.371B Estimate

Ambac Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.09 by 811.11 percent. This is a 373.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported $103.000 million in sales this quarter. This is a 77.59 percent increase over sales of $58.000 million the same period last year.

AMBC

Ambac Financial Group Q1 2024 Adj EPS $0.82 Beats $0.09 Estimate, Sales $103.000M Up From $58.000M YoY

Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) by 8 percent. This is a 39.47 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $194.947 million which beat the analyst consensus estimate of $187.112 million by 4.19 percent. This is a 23.70 percent increase over sales of $157.602 million the same period last year.

ZETA

Zeta Global Holdings Q1 2024 GAAP EPS $(0.23) Beats $(0.25) Estimate, Sales $194.947M Beat $187.112M Estimate

Mueller Water Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.14 by 114.29 percent. The company reported quarterly sales of $353.400 million which beat the analyst consensus estimate of $299.617 million by 17.95 percent. This is a 6.16 percent increase over sales of $332.900 million the same period last year.

Mueller Water Products Q2 2024 Adj EPS $0.30 Beats $0.14 Estimate, Sales $353.400M Beat $299.617M Estimate

Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) reported quarterly earnings of $1.78 per share which beat the analyst consensus estimate of $1.66 by 7.23 percent. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.05 billion by 2.49 percent. This is a 1.36 percent decrease over sales of $1.03 billion the same period last year.

Cabot Q2 2024 Adj EPS $1.78 Beats $1.66 Estimate, Sales $1.02B Miss $1.05B Estimate

Second Quarter 2024 Outlook:
<ul>
<li>Revenue of $100.0 - $105.0 million.</li>
<li>Variable Marketing Margin of $31.0 - $33.0 million.</li>
<li>Adjusted EBITDA of $7.0 - $9.0 million.</li>
</ul>
With respect to the Company's expectations under "Second Quarter 2024 Outlook" above, the Company has not reconciled the non-GAAP measure Adjusted EBITDA to the GAAP measure net income (loss) in this press release because the Company does not provide guidance for stock-based compensation expense, depreciation and amortization expense, restructuring and other charges, acquisition-related costs, interest income, and income taxes on a consistent basis as the Company is unable to quantify these amounts without unreasonable efforts, which would be required to include a reconciliation of Adjusted EBITDA to GAAP net income (loss). In addition, the Company believes such a reconciliation would imply a degree of precision that could be confusing or misleading to investors.

EVER

EverQuote Sees Q2 2024 Revenue $100M-$105M Vs $77.29M Est.

The Company expects revenues to be in the range of&nbsp;$386&nbsp;to&nbsp;$396 million&nbsp;compared to the previously articulated range of&nbsp;$382&nbsp;to&nbsp;$396 million (consensus $388.028 million). At current rates, the Company expects negligible year-over-year currency impact on the full year 2024 revenues.
Additionally, Artivion continues to expect non-GAAP adjusted EBITDA to increase between&nbsp;26%&nbsp;and&nbsp;34%&nbsp;for the full year 2024 compared to 2023, resulting in 2024 non-GAAP adjusted EBITDA in the range of&nbsp;$68&nbsp;to&nbsp;$72 million.

AORT

Artivion Revises FY24 Revenue Guidance From 8%-12% To 9%-12% Y/Y Growth On Constant Currency Basis

RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.27) by 55.56 percent. This is a 61.29 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $29.512 million which beat the analyst consensus estimate of $27.559 million by 7.09 percent. This is a 68.75 percent increase over sales of $17.489 million the same period last year.

RXST

RxSight Q1 2024 Adj EPS $(0.12) Beats $(0.27) Estimate, Sales $29.512M Beat $27.559M Estimate

EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.07) by 171.43 percent. This is a 162.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $91.06 million which beat the analyst consensus estimate of $80.31 million by 13.39 percent. This is a 16.62 percent decrease over sales of $109.22 million the same period last year.

EverQuote Q1 EPS $0.05 Beats $(0.07) Estimate, Sales $91.06M Beat $80.31M Estimate

Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.66) by 9.09 percent.

DAWN

Day One Biopharmaceutical Q1 2024 GAAP EPS $(0.72) Misses $(0.66) Estimate

New Providence Acquisition Corp. II (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPABU#NASDAQ">NPABU</a>) announced today that on May 5, 2024 New Providence Acquisition Corp. II ("NPA") entered into a non‑binding letter of intent for a potential business combination with a company in the consumer sector. No assurance can be made that NPA will successfully negotiate and enter into a definitive agreement for a business combination or that NPA will be successful in completing a business combination.

NPAB

NPABU

New Providence Acquisition Corp. II Announces Entry Into Non-Binding LOI For A Potential Business Combination In The Consumer Sector

TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.37) by 108.11 percent. This is a 150 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $402.853 million which beat the analyst consensus estimate of $400.367 million by 0.62 percent. This is a 13.42 percent decrease over sales of $465.288 million the same period last year.

TrueBlue Q1 2024 Adj EPS $0.03 Beats $(0.37) Estimate, Sales $402.853M Beat $400.367M Estimate

OpGen files to sell 10.89M shares to holders

OpGen GAAP EPS of -$0.46 misses by $0.03, revenue of $0.7M misses by $0.15M

OpGen Inc (OPGN) has released an update to notify the public and investors about the unregistered sales of equity securities. The recent report hig...

OpGen Inc Reports Unregistered Equity Sales Update

OpGen Inc (OPGN) has released an update to notify the public and investors about an entry into a material definitive agreement. OpGen, Inc. has rea...

OpGen Inc. Extends Warrant Exercise Deadline to 2024

OpGen Inc (OPGN) has released an update. OpGen, Inc., facing the threat of being delisted from Nasdaq due to not meeting the minimum bid price requ...

OpGen Inc Granted Extension to Meet Nasdaq Compliance

OpGen stock jumps after David Lazar invests $3M, takes over as CEO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!



Moving stocks this morning are pharmaceutical updates, earnings reports, collaboration agreements and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Stoke Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/stok-stock-quote/">STOK</a>) stock is rocketing more than 81% alongside <a href="https://www.nasdaq.com/press-release/stoke-therapeutics-announces-landmark-new-data-that-support-the-potential-for-stk-001">positive Phase 1/2a studies data</a>.</li>



<li>Check-Cap (NASDAQ:<a href="https://investorplace.com/stock-quotes/chek-stock-quote/">CHEK</a>) shares are soaring over 35% after announcing a <a href="https://www.nasdaq.com/press-release/nobul-ai-corp-and-check-cap-ltd-enter-into-definitive-business-combination-agreement">business combination agreement</a>.</li>



<li>OpGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/opgn-stock-quote/">OPGN</a>) stock is surging more than 30% after announcing the <a href="https://ir.opgen.com/news-releases/news-release-details/opgen-announces-acquisition-preferred-stock-david-lazar">acquisition of its preferred shares</a>.</li>



<li>C3is (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciss-stock-quote/">CISS</a>) shares are rising over 25% as it <a href="https://c3is.pro/c3is-inc-announces-the-date-for-the-release-of-the-fourth-quarter-and-twelve-months-2023-financial-and-operating-results/investor-relations/press-releases/">prepares to release earnings</a>.</li>



<li>Krispy Kreme (NASDAQ:<a href="https://investorplace.com/stock-quotes/dnut-stock-quote/">DNUT</a>) stock is increasing more than 22% on <a href="https://www.cnbc.com/2024/03/26/mcdonalds-to-sell-krispy-kreme-doughnuts-nationwide-by-end-of-2026.html">a collaboration with McDonald&rsquo;s</a> (NYSE:<a href="https://investorplace.com/stock-quotes/mcd-stock-quote/">MCD</a>).</li>



<li>Mesoblast (NASDAQ:<a href="https://investorplace.com/stock-quotes/meso-stock-quote/">MESO</a>) shares are gaining over 21% alongside <a href="https://www.nasdaq.com/press-release/united-states-food-drug-administration-fda-notifies-mesoblast-that-available-clinical">an update on a drug submission</a>.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock is climbing more than 16% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318185017&amp;type=PDF&amp;symbol=ALLR&amp;cdn=4c6b3ee332556111dd440255ac861084&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=S-8&amp;formDescription=Registration+statement+under+Securities+Act+of+1933+to+be+offered+to+employees+pursuant+to+certain+plans&amp;dateFiled=2024-03-25">updating its Equity Incentive Plan</a>.</li>



<li>Intelligent (NASDAQ:<a href="https://investorplace.com/stock-quotes/intj-stock-quote/">INTJ</a>) shares are getting an over 14% boost without any clear news this morning.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is jumping more than 14% on Tuesday morning.</li>



<li>XTL Biopharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/">XTLB</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Tidal Trust II YieldMax MRNA Option Income Strategy ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/mrny-stock-quote/">MRNY</a>) stock is plummeting 60% this morning.</li>



<li>NeuBase Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nbse-stock-quote/">NBSE</a>) shares are crashing more than 54% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318184533&amp;type=PDF&amp;symbol=NBSE&amp;cdn=3014c60622ce95fc448919cc3936cd2b&amp;companyName=NeuBase+Therapeutics+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-03-25">special shareholder meeting</a>.</li>



<li>AppTech Payments (NASDAQ:<a href="https://investorplace.com/stock-quotes/apcx-stock-quote/">APCX</a>) stock is diving close to 43% after <a href="https://www.nasdaq.com/press-release/apptech-payments-corp.-announces-proposed-underwritten-public-offering-of-common">proposing a share offering</a>.</li>



<li>The Real Good Food (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgf-stock-quote/">RGF</a>) shares are dropping over 19% on Tuesday.</li>



<li>Next e GO (NASDAQ:<a href="https://investorplace.com/stock-quotes/egox-stock-quote/">EGOX</a>) stock is taking a more than 18% beating <a href="https://investorplace.com/2024/03/why-is-next-e-go-egox-stock-up-86-today/">after a recent rally</a>.</li>



<li>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) shares are tumbling over 18% alongside its <a href="https://finance.yahoo.com/news/effector-therapeutics-reports-fourth-quarter-200100641.html">latest earnings report</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) stock is decreasing more than 16% with the release of its <a href="https://investorplace.com/earning-results/2024/03/tivc-stock-earnings-tivic-health-systems-for-q4-of-2023/">Q4 earnings report</a>.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) shares are sliding over 12% after releasing its <a href="https://www.marketscreener.com/quote/stock/KAIVAL-BRANDS-INNOVATIONS-111314401/news/Kaival-Brands-Innovations-Group-Inc-Reports-Earnings-Results-for-the-First-Quarter-Ended-January-3-46281052/">most recent earnings report</a>.</li>



<li>Tuniu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tour-stock-quote/">TOUR</a>) stock is falling more than 10% this morning.</li>



<li>Westport Fuel Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/wprt-stock-quote/">WPRT</a>) shares close out our pre-market stock movers down over 10% <a href="https://seekingalpha.com/article/4680367-westport-fuel-systems-stock-q4-earnings-review-maintain-hold">alongside Q4 earnings</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-march-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

OpGen Inc (OPGN) just unveiled an update. OpGen, Inc. has struck a deal with investor David E. Lazar, who will purchase 3 million shares of Series ...

OpGen Inc Secures $3M Investment, Enhances Corporate Structure

The latest update is out from OpGen Inc (OPGN). OpGen, Inc. has appointed David Lazar as its new CEO, effective April 1, 2024, with an annual salar...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

OpGen Stock (NASDAQ:OPGN), Short Interest Report

People Also Watch